Ardelyx Announced The Publication Of Results From The T3MPO-3 Long-term Open-label Safety Trial Of Ibsrela (Tenapanor) For Irritable Bowel Syndrome With Constipation In The Journal Of Neurogastroenterology And Motility
Ardelyx Announced The Publication Of Results From The T3MPO-3 Long-term Open-label Safety Trial Of Ibsrela (Tenapanor) For Irritable Bowel Syndrome With Constipation In The Journal Of Neurogastroenterology And Motility
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.